Clinical trial NCT00135499 (phase 3, status: terminated)
Conditions: lymphoma, large-cell, diffuse
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone, prednisone, doxorubicin, cyclophosphamide, vincristine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@@H]5C[N@@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    recruitment too low
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with diffuse large B-cell lymphoma according to the WHO classification (anti
             CD20 labeling)

          -  Aged from 60 to 65 years.

          -  Not previously treated.

          -  Ann Arbor stage II, III, IV.

          -  ECOG performance status 0 to 2.

          -  Minimum life expectancy of 3 months.

          -  Negative HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies test 4
             weeks (except after vaccination).

          -  Having previously signed a written informed consent.

        Exclusion Criteria:

          -  T-cell lymphoma.

          -  Any history of treated or non-treated indolent lymphoma. However, patients not
             previously diagnosed and having a diffuse large B-cell lymphoma with some small cell
             infiltration in bone marrow or lymph node may be included.

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Contra-indication to any drug contained in the chemotherapy regimens.

          -  Any serious active disease (according to the investigator's decision).

          -  Poor renal function (creatinine level>150micromol/l), poor hepatic function (total
             bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these
             abnormalities are related to the lymphoma.

          -  Poor bone marrow reserve as defined by neutrophils<1.5G/l or platelets<100G/l, unless
             related to bone marrow infiltration.

          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma.

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Adult patient under tutelage.